Eli Lilly – LY2624803 – Treatment Of Chronic Insomnia

Eli Lilly – LY2624803 – Treatment Of Chronic Insomnia

Company: Eli Lilly
Development Status: Phase 2
Therapeutic Area: Central Nervous System
Compound/Vaccine: LY2624803
Product Description: 5-HT2A and Histamine H1 Receptor Antagonist
Current Indication: Chronic Insomnia

Treatment of Chronic Insomnia

LY2624803 is in phase 2 of clinical trials for the treatment of chronic insomnia. The compound is a 5-HT2A and histamine H1 receptor antagonist from Eli Lilly as part of its product line-up for therapeutics for the central nervous system. The study is currently recruiting participants for the evaluation of the efficacy and safety of LY2624803. The study will evaluate the compound in comparison with a placebo as well as zolpidem. The study is designed to be a randomized, double-blind, placebo controlled crossover assignment. The tests for the safety and efficacy of LY2624803 will be conducted on outpatients in an active comparator controlled study. The primary outcomes of the phase 2 of trials will measure the average nightly total sleep time of a patient which will be calculated from a daily sleep questionnaire.

Chronic Insomnia

Insomnia is a condition of sleeplessness which every adult goes through at one point or another in their life. It is described as difficulty in initiating or maintaining sleep or both. Insomnia has been recognized as a symptom rather than a stand-alone diagnosis or disease. An estimated 10% of the general population is affected by chronic insomnia. Chronic insomnia is wherein the condition persists for more than three weeks. Chronic insomnia may be caused due to a variety of reasons which includes underlying psychiatric or physiologic conditions. Insomnia is also considered as an indicator of depression. The condition also has daytime symptoms like poor concentration and focus, difficulty with memory, impaired motor coordination and irritability along with impaired social interaction.

Comments are closed.